Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease - PubMed (original) (raw)
. 2002 Jul 1;100(1):59-66.
doi: 10.1182/blood.v100.1.59.
Claudia Schoch, Martin Dugas, Wolfgang Kern, Peter Staib, Christian Wuchter, Helmut Löffler, Cristina Maria Sauerland, Hubert Serve, Thomas Büchner, Torsten Haferlach, Wolfgang Hiddemann
Affiliations
- PMID: 12070009
- DOI: 10.1182/blood.v100.1.59
Free article
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
Susanne Schnittger et al. Blood. 2002.
Free article
Abstract
FLT3 length mutation (FLT3-LM) is a molecular marker potentially useful for the characterization of acute myeloid leukemia (AML). To evaluate the distribution of FLT3-LM within biologic subgroups, we screened 1003 patients with AML at diagnosis for this mutation. FLT3-LM was found in 234 (23.5%) of all patients and thus is the most frequent mutation in AML described so far. Of all positive patients, 165 (70.5%) revealed a normal karyotype. Of the 69 patients with chromosome aberrations, 24 (34.8%) had a t(15;17). The mutation was rare in AML with t(8;21), inv(16) 11q23 rearrangements, and complex karyotypes. FLT3-LM was not distributed equally within different French-American-British (FAB) subtypes and was correlated with a high peripheral blood count in FAB M1, M2, and M4 (P <.0001). In addition, the median age of patients with the mutation was lower (54.9 vs 57.6 years; P =.043), and, at a ratio of 1.36:1 (P =.023), the mutation was more frequent in females than in males. Within the AMLCG study, FLT3-LM was of intermediate prognostic significance. The complete remission rate of 70.3% in patients with FLT3-LM was similar to that (70.4%) in patients without FLT3-LM. Overall survival was not different between patients with or without FLT3-LM. In contrast, patients with FLT3-LM had a significantly shorter event-free survival (7.4 vs 12.6 months; P =.0072) because of a higher relapse rate. Besides the importance of FLT3-LM for biologic and clinical characterization of AML, we show its value as a marker for disease monitoring based on 120 follow-up samples of 34 patients.
Similar articles
- FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia.
Schnittger S, Schoch C, Kern W, Hiddemann W, Haferlach T. Schnittger S, et al. Acta Haematol. 2004;112(1-2):68-78. doi: 10.1159/000077561. Acta Haematol. 2004. PMID: 15179006 Review. - Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R, Ueda R. Kiyoi H, et al. Blood. 1999 May 1;93(9):3074-80. Blood. 1999. PMID: 10216104 Clinical Trial. - Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F, Kern W, Schoch C, Kohlmann A, Hiddemann W, Haferlach T, Schnittger S. Kuchenbauer F, et al. Haematologica. 2005 Dec;90(12):1617-25. Haematologica. 2005. PMID: 16330434 - Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication.
Muñoz L, Aventín A, Villamor N, Juncà J, Acebedo G, Domingo A, Rozman M, Torres JP, Tormo M, Nomdedéu JF. Muñoz L, et al. Haematologica. 2003 Jun;88(6):637-45. Haematologica. 2003. PMID: 12801839 Clinical Trial. - Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics.
Marcucci G, Mrózek K, Bloomfield CD. Marcucci G, et al. Curr Opin Hematol. 2005 Jan;12(1):68-75. doi: 10.1097/01.moh.0000149608.29685.d1. Curr Opin Hematol. 2005. PMID: 15604894 Review.
Cited by
- Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase.
Walter W, Nadarajah N, Hutter S, Müller H, Haferlach C, Kern W, Haferlach T, Meggendorfer M. Walter W, et al. Leukemia. 2024 Sep 28. doi: 10.1038/s41375-024-02425-1. Online ahead of print. Leukemia. 2024. PMID: 39341969 - Prognostic Factors of Pediatric Acute Myeloid Leukemia Patients with t(8;21) (q22;q22): A Single-Center Retrospective Study.
Yang J, Zhu X, Zhang H, Fu Y, Li Z, Xing Z, Yu Y, Cao P, Le J, Jiang J, Li J, Wang H, Zhai X. Yang J, et al. Children (Basel). 2024 May 17;11(5):605. doi: 10.3390/children11050605. Children (Basel). 2024. PMID: 38790600 Free PMC article. - Targeting BMAL1 reverses drug resistance of acute myeloid leukemia cells and promotes ferroptosis through HMGB1-GPX4 signaling pathway.
Zheng H, Wu T, Lin Z, Wang D, Zhang J, Zeng T, Liu L, Shen J, Zhao M, Li JD, Yang M. Zheng H, et al. J Cancer Res Clin Oncol. 2024 May 4;150(5):231. doi: 10.1007/s00432-024-05753-y. J Cancer Res Clin Oncol. 2024. PMID: 38703241 Free PMC article. - Novel Therapeutic Targets in Acute Myeloid Leukemia (AML).
Wysota M, Konopleva M, Mitchell S. Wysota M, et al. Curr Oncol Rep. 2024 Apr;26(4):409-420. doi: 10.1007/s11912-024-01503-y. Epub 2024 Mar 19. Curr Oncol Rep. 2024. PMID: 38502417 Free PMC article. Review. - The Clinical Utility of FLT3 Mutation Testing in Acute Leukemia: A Canadian Consensus.
Bergeron J, Capo-Chichi JM, Tsui H, Mahe E, Berardi P, Minden MD, Brandwein JM, Schuh AC. Bergeron J, et al. Curr Oncol. 2023 Dec 12;30(12):10410-10436. doi: 10.3390/curroncol30120759. Curr Oncol. 2023. PMID: 38132393 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous